Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response.

Szymonowicz K, Oeck S, Malewicz NM, Jendrossek V.

Cancers (Basel). 2018 Mar 18;10(3). pii: E78. doi: 10.3390/cancers10030078. Review.

2.

Functional role of AKT signaling in bovine early embryonic development: potential link to embryotrophic actions of follistatin.

Ashry M, Rajput SK, Folger JK, Knott JG, Hemeida NA, Kandil OM, Ragab RS, Smith GW.

Reprod Biol Endocrinol. 2018 Jan 8;16(1):1. doi: 10.1186/s12958-017-0318-6.

3.

Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.

Wu S, Wang S, Gao F, Li L, Zheng S, Yung WKA, Koul D.

Neuro Oncol. 2018 Jan 10;20(1):78-91. doi: 10.1093/neuonc/nox128.

PMID:
29016926
4.

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.

Wee P, Wang Z.

Cancers (Basel). 2017 May 17;9(5). pii: E52. doi: 10.3390/cancers9050052. Review.

5.

Functional Effects of AKT3 on Aurora Kinase Inhibitor-induced Aneuploidy.

Noguchi K, Hongama K, Hariki S, Nonomiya Y, Katayama K, Sugimoto Y.

J Biol Chem. 2017 Feb 3;292(5):1910-1924. doi: 10.1074/jbc.M116.747048. Epub 2016 Dec 27.

6.

RSK1 protects P-glycoprotein/ABCB1 against ubiquitin-proteasomal degradation by downregulating the ubiquitin-conjugating enzyme E2 R1.

Katayama K, Fujiwara C, Noguchi K, Sugimoto Y.

Sci Rep. 2016 Oct 27;6:36134. doi: 10.1038/srep36134.

7.

Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy.

Hu T, Zhou R, Zhao Y, Wu G.

Sci Rep. 2016 Sep 14;6:33376. doi: 10.1038/srep33376.

8.

Identification of Phosphorylated Cyclin-Dependent Kinase 1 Associated with Colorectal Cancer Survival Using Label-Free Quantitative Analyses.

Lin PC, Yang YF, Tyan YC, Hsiao ES, Chu PC, Lee CT, Lee JC, Chen YM, Liao PC.

PLoS One. 2016 Jul 6;11(7):e0158844. doi: 10.1371/journal.pone.0158844. eCollection 2016.

9.

Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.

Castel P, Toska E, Zumsteg ZS, Carmona FJ, Elkabets M, Bosch A, Scaltriti M.

Mol Cell Oncol. 2014 Oct 29;1(3):e963447. doi: 10.4161/23723548.2014.963447. eCollection 2014 Jul-Sep. Review.

10.

Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.

Toledo CM, Ding Y, Hoellerbauer P, Davis RJ, Basom R, Girard EJ, Lee E, Corrin P, Hart T, Bolouri H, Davison J, Zhang Q, Hardcastle J, Aronow BJ, Plaisier CL, Baliga NS, Moffat J, Lin Q, Li XN, Nam DH, Lee J, Pollard SM, Zhu J, Delrow JJ, Clurman BE, Olson JM, Paddison PJ.

Cell Rep. 2015 Dec 22;13(11):2425-2439. doi: 10.1016/j.celrep.2015.11.021. Epub 2015 Dec 7.

11.

Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?

Singh SS, Yap WN, Arfuso F, Kar S, Wang C, Cai W, Dharmarajan AM, Sethi G, Kumar AP.

World J Gastroenterol. 2015 Nov 21;21(43):12261-73. doi: 10.3748/wjg.v21.i43.12261. Review.

12.

Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B.

Potts MB, McMillan EA, Rosales TI, Kim HS, Ou YH, Toombs JE, Brekken RA, Minden MD, MacMillan JB, White MA.

Nat Chem Biol. 2015 Jun;11(6):401-8. doi: 10.1038/nchembio.1797. Epub 2015 Apr 13.

13.

Cables1 complex couples survival signaling to the cell death machinery.

Shi Z, Park HR, Du Y, Li Z, Cheng K, Sun SY, Li Z, Fu H, Khuri FR.

Cancer Res. 2015 Jan 1;75(1):147-158. doi: 10.1158/0008-5472.CAN-14-0036. Epub 2014 Oct 31.

14.

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.

Zhou L, Zhang Y, Chen S, Kmieciak M, Leng Y, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Dai Y, Grant S.

Leukemia. 2015 Apr;29(4):807-18. doi: 10.1038/leu.2014.296. Epub 2014 Oct 6.

15.

Silencing of Dicer1 temporally separates pro- and anti-apoptotic signaling and confers susceptibility to chemotherapy in p53 mutated cells.

Nekova TS, Kneitz S, Einsele H, Stuhler G.

Cell Cycle. 2014;13(14):2192-8. doi: 10.4161/cc.29216. Epub 2014 May 20.

16.

Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models.

Zhang X, Lv H, Zhou Q, Elkholi R, Chipuk JE, Reddy MV, Reddy EP, Gallo JM.

Mol Cancer Ther. 2014 May;13(5):1105-16. doi: 10.1158/1535-7163.MCT-13-0847. Epub 2014 Feb 25.

17.

Systematically studying kinase inhibitor induced signaling network signatures by integrating both therapeutic and side effects.

Shao H, Peng T, Ji Z, Su J, Zhou X.

PLoS One. 2013 Dec 5;8(12):e80832. doi: 10.1371/journal.pone.0080832. eCollection 2013.

18.

DDAH1 deficiency attenuates endothelial cell cycle progression and angiogenesis.

Zhang P, Xu X, Hu X, Wang H, Fassett J, Huo Y, Chen Y, Bache RJ.

PLoS One. 2013 Nov 18;8(11):e79444. doi: 10.1371/journal.pone.0079444. eCollection 2013.

19.

PIK3R1 underexpression is an independent prognostic marker in breast cancer.

Cizkova M, Vacher S, Meseure D, Trassard M, Susini A, Mlcuchova D, Callens C, Rouleau E, Spyratos F, Lidereau R, Bièche I.

BMC Cancer. 2013 Nov 14;13:545. doi: 10.1186/1471-2407-13-545.

20.

Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Chen J.

World J Virol. 2012 Dec 12;1(6):154-61. doi: 10.5501/wjv.v1.i6.154. Review.

Supplemental Content

Support Center